Abstract
Background
In this study, we evaluated the performance of Elite microplate analyzer (Bio-Rad Laboratories, France) and the related assays (ULTRA line) for the detection of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Methods
Seroconversion panels, HBsAg positive/HBsAg negative (n=99/n=1,422), anti-HCV positive/negative (n=97/n=1,670), and anti-HIV positive/negative (n=112/n=1,704) samples were used to evaluate the performance of Monolisa HBsAg ULTRA, Monolisa HCV Ag-Ab ULTRA, and Genscreen ULTRA HIV Ag-Ab, respectively. The agreement of Elite microplate analyzer with CODA analyzer (Bio-Rad Laboratories, CA, USA) was also evaluated.
Results
The detection limit of Monolisa HBsAg ULTRA was 0.034 IU/mL. For Monolisa HBsAg ULTRA, Monolisa HCV Ag-Ab ULTRA, and Genscreen ULTRA HIV Ag-Ab, diagnostic sensitivities were all 100%, diagnostic specificities were 100%, 99.8% and 99.9%, and total CVs (coefficients of variation) were 13.8–17.5%, 3.4–5.2%, and 7.5–9.5%, respectively. The agreement of Elite microplate analyzer with CODA analyzer was 99.5%.
Conclusions
The performance of Elite microplate analyzer and the related assays on analytical sensitivity, precision, early detection, diagnostic sensitivity and specificity was all adequate for a mass screening. However, further large multi-center studies should be performed to validate our results.
Go to : 

References
1. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; Approved guideline. Document EP5-A.Vilanova, Pa: National Committee for Clinical Laboratory Standards;1999.
2. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159–74.


4. Weber B, Muhlbacher A, Melchior W. Detection of an acute asymptomatic HBsAg negative hepatitis B virus infection in a blood donor by HBV DNA testing. J Clin Virol. 2005; 32:67–70.


5. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion. 2001; 41:878–84.


6. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996; 334:1685–90.
7. Seo DH. Transfusion-transmitted diseases: current state and recent countermeasures. J Korean Med Assoc. 2006; 49:410–5.


8. Carman WF, Van Deursen FJ, Mimms LT, Hardie D, Coppola R, Decker R, et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology. 1997; 26:1658–66.


9. Howard CR. The structure of hepatitis B envelope and molecular variants of hepatitis B virus. J Viral Hepat. 1995; 2:165–70.


10. Weber B, Dengler T, Berger A, Doerr HW, Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBs-Ag. J Clin Microbiol. 2003; 41:135–43.


11. Weber B, Van der Taelem-Brule N, Berger A, Simon F, Geudin M, Ritter J. Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg Ultra. J Virol Methods. 2006; 135:109–17.


12. Weber B, Bayer A, Kirch P, Schluter V, Schlieper D, Melchior W. Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. J Clin Microbiol. 1999; 37:2639–47.


13. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods. 2004; 115:217–22.


14. Howard CR, Allison LM. Hepatitis B surface antigen variation and protective immunity. Intervirology. 1995; 38:35–40.


15. Coleman PF, Chen YC, Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol. 1999; 59:19–24.


16. Louisirirotchanakul S, Kanoksinsombat C, Theamboonlert A, Puthavatana P, Wasi C, Poovorawan Y. Mutation of the “a” determinant of HBsAg with discordant HBsAg diagnostic kits. Viral Immunol. 2004; 17:440–4.


17. Jongerius JM, Wester M, Cuypers HT, van Oostendorp WR, Lelie PN, van der Poel CL, et al. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion. 1998; 38:56–9.


18. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005; 32:102–12.


19. Weber B. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol. 2006; 78(S1):):S59–65.


20. Ly TD, Servant-Delmas A, Bagot S, Gonzalo S, Ferey MP, Ebel A, et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol. 2006; 44:2321–6.


21. van Helden J, Denoyel GA. Experience with the IVDD performance evaluations of the ADVIA Centaur infectious disease assays. J Clin Virol. 2004; 30:S16–8.


22. Hennig H, Schlenke P, Kirchner H, Bauer I, Schulte-Kellinghaus B, Bludau H. Evaluation of newly developed microparticle enzyme immunoassays for the detection of HCV antibodies. J Virol Methods. 2000; 84:181–90.


23. Schappert J, Wians FH Jr, Schiff E, Smalley D, Gambardella R, Lee WM, et al. Multicenter evaluation of the Bayer ADVIA Centaur HIV 1/O/2 enhanced (EHIV) assay. Clin Chim Acta. 2006; 372:158–66.


24. Sickinger E, Stieler M, Kaufman B, Kapprell HP, West D, Sandridge A, et al. Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen. J Clin Microbiol. 2004; 42:21–9.


25. Kang HJ, Yoo KH, Kim HS, Cho HC. Evaluation of Abbott fourth generation HIV antigen and antibody assays. Korean J Lab Med. 2006; 26:39–44.


26. Laperche S, Bouchardeau F, Maniez M, Beolet M, Elghouzzi MH, Lefrere JJ. Nucleic acid testing in blood donations reactive to hepatitis C virus antibody, but with an extremely low viral load. Vox Sang. 2004; 86:198.


27. Jonas G, Pelzer C, Beckert C, Hausmann M, Kapprell HP. Performance characteristics of the ARCHITECT anti-HCV assay. J Clin Virol. 2005; 34:97–103.


Go to : 

Table 1.
Low detection limit of Monolisa HBsAg ULTRA test for HBsAg WHO standard material
Table 2.
Precision performance of Bio-Rad ULTRA line kits on Elite microplate system
Table 3.
Comparison of the performance of Elite microplate system, Abbott Prism and Abbott AxSYM version 2 in seroconversion panels
Panel serial No. | Days since 1st bleed | Elite microplate (S/C ratio) | Abbott Prism* (S/C ratio) | Abbott AxSYM version 2* (S/C ratio) |
---|---|---|---|---|
HBV BBI | ||||
PHM935A–02 | 2 | 0.1 | 0.5 | 0.4 |
PHM935A–03 | 7 | 0.2 | 0.7 | 0.4 |
PHM935A–04 | 9 | 0.2 | 0.3 | 0.4 |
PHM935A–05 | 14 | 0.1 | 0.4 | 0.4 |
PHM935A–06 | 16 | 0.2 | 0.6 | 0.4 |
PHM935A–07 | 21 | 1.5 | 1.8 | 0.7 |
HCV BBI | ||||
PHV916–02 | 2 | 0.6 | 0.1 | 0.4 |
PHV916–03 | 7 | 0.1 | 0.1 | 0.3 |
PHV916–04 | 9 | 1.0 | 0.2 | 0.4 |
PHV916–05 | 16 | 0.8 | 1.0 | 0.2 |
PHV916–06 | 19 | 2.2 | 1.9 | 4.4 |
PHV916–07 | 23 | 3.4 | 2.7 | 15.5 |
HIV BBI | ||||
PRB931–02 | 2 | 0.4 | 0.3 | 0.4 |
PRB931–03 | 7 | 0.4 | 0.4 | 0.3 |
PRB931–04 | 9 | 0.5 | 0.3 | 0.4 |
PRB931–05 | 15 | 0.9 | 0.3 | 0.4 |
PRB931–06 | 28 | 37.8 | 7.0 | 7.5 |
PRB931–07 | 33 | 37.8 | 64.9 | 14.2 |
Table 4.
Summary of the diagnostic sensitivity and specificity of Bio-Rad Monolisa HBsAg, HCV Ag-Ab, and Genscreen HIV Ag-Ab ULTRA kits on Elite microplate system
Table 5.
Comparison of anti-HCV results of LG HCV Ab 3.0 EIA test kit (LG chemicals, Seoul, Korea) performed on the different automatic analyzers, CODA system and Elite microplate system
LG HCV Ab test on Elite system |
Total | Kappa† | |||
---|---|---|---|---|---|
Positive | Negative | ||||
LG HCV Ab test on CODA system | Positive | 30 | 6* | 36 | 0.88 |
Negative | 2* | 1,494 | 1,496 | ||
Total | 32 | 1,500 | 1,532 |